The ongoing Zika epidemic and its consequences demand rapid development of a safe, efficacious vaccine. As preclinical studies of vaccine candidates continue in parallel with human trials, we need to determine which questions will inform short-term development plans.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2016) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: